52 related articles for article (PubMed ID: 10926118)
1. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.
Jakobsen H; Schulz D; Pizza M; Rappuoli R; Jónsdóttir I
Infect Immun; 1999 Nov; 67(11):5892-7. PubMed ID: 10531245
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers.
Banerjee S; Medina-Fatimi A; Nichols R; Tendler D; Michetti M; Simon J; Kelly CP; Monath TP; Michetti P
Gut; 2002 Nov; 51(5):634-40. PubMed ID: 12377799
[TBL] [Abstract][Full Text] [Related]
3. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.
Beignon AS; Briand JP; Muller S; Partidos CD
Immunology; 2001 Mar; 102(3):344-51. PubMed ID: 11298834
[TBL] [Abstract][Full Text] [Related]
4. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection.
Kleanthous H; Myers GA; Georgakopoulos KM; Tibbitts TJ; Ingrassia JW; Gray HL; Ding R; Zhang ZZ; Lei W; Nichols R; Lee CK; Ermak TH; Monath TP
Infect Immun; 1998 Jun; 66(6):2879-86. PubMed ID: 9596763
[TBL] [Abstract][Full Text] [Related]
5. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses.
Ermak TH; Giannasca PJ; Nichols R; Myers GA; Nedrud J; Weltzin R; Lee CK; Kleanthous H; Monath TP
J Exp Med; 1998 Dec; 188(12):2277-88. PubMed ID: 9858514
[TBL] [Abstract][Full Text] [Related]
6. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.
Richards CM; Aman AT; Hirst TR; Hill TJ; Williams NA
J Virol; 2001 Feb; 75(4):1664-71. PubMed ID: 11160664
[TBL] [Abstract][Full Text] [Related]
7. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.
Scharton-Kersten T; Yu Jm; Vassell R; O'Hagan D; Alving CR; Glenn GM
Infect Immun; 2000 Sep; 68(9):5306-13. PubMed ID: 10948159
[TBL] [Abstract][Full Text] [Related]
8. Immunization against natural Helicobacter pylori infection in nonhuman primates.
Dubois A; Lee CK; Fiala N; Kleanthous H; Mehlman PT; Monath T
Infect Immun; 1998 Sep; 66(9):4340-6. PubMed ID: 9712786
[TBL] [Abstract][Full Text] [Related]
9. Parenteral immunization with a cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) adjuvanted
Chen J; Zhong Y; Liu Y; Tang C; Zhang Y; Wei B; Chen W; Liu M
Hum Vaccin Immunother; 2020 Nov; 16(11):2849-2854. PubMed ID: 32298215
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.
Davtyan H; Ghochikyan A; Hovakimyan A; Petrushina I; Yu J; Flyer D; Madsen PJ; Pedersen LO; Cribbs DH; Agadjanyan MG
J Neuroimmunol; 2014 Mar; 268(1-2):50-7. PubMed ID: 24507620
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization.
Barackman JD; Ott G; Pine S; O'Hagan DT
Clin Diagn Lab Immunol; 2001 May; 8(3):652-7. PubMed ID: 11329476
[TBL] [Abstract][Full Text] [Related]
12. Cytokines: the future of intranasal vaccine adjuvants.
Thompson AL; Staats HF
Clin Dev Immunol; 2011; 2011():289597. PubMed ID: 21826181
[TBL] [Abstract][Full Text] [Related]
13. Mucosal adjuvanticity and mucosal booster effect of colibactin-depleted probiotic
Uchiyama H; Kudo T; Yamaguchi T; Obana N; Watanabe K; Abe K; Miyazaki H; Toyofuku M; Nomura N; Akeda Y; Nakao R
Hum Vaccin Immunother; 2024 Dec; 20(1):2337987. PubMed ID: 38658133
[TBL] [Abstract][Full Text] [Related]
14. NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant.
Hall LJ; Clare S; Dougan G
J Immunol; 2010 Apr; 184(8):4327-37. PubMed ID: 20220095
[TBL] [Abstract][Full Text] [Related]
15. The design of new adjuvants for mucosal immunity to Neisseria meningitidis B in nasally primed neonatal mice for adult immune response.
Ferreira T; De Gaspari E
ScientificWorldJournal; 2012; 2012():292073. PubMed ID: 22545012
[TBL] [Abstract][Full Text] [Related]
16. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.
Connell TD
Expert Rev Vaccines; 2007 Oct; 6(5):821-34. PubMed ID: 17931161
[TBL] [Abstract][Full Text] [Related]
17. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
[TBL] [Abstract][Full Text] [Related]
18. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.
Weltzin R; Guy B; Thomas WD; Giannasca PJ; Monath TP
Infect Immun; 2000 May; 68(5):2775-82. PubMed ID: 10768972
[TBL] [Abstract][Full Text] [Related]
19. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
